Fishman Jay A Ltd. MI Sells 17,221 Shares of Pfizer, Inc. (PFE)

Fishman Jay A Ltd. MI cut its position in shares of Pfizer, Inc. (NYSE:PFE) by 2.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 734,393 shares of the biopharmaceutical company’s stock after selling 17,221 shares during the quarter. Pfizer makes up about 5.2% of Fishman Jay A Ltd. MI’s holdings, making the stock its 5th biggest position. Fishman Jay A Ltd. MI’s holdings in Pfizer were worth $24,668,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Northstar Group Inc. boosted its holdings in Pfizer by 0.4% during the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 35 shares during the last quarter. River Wealth Advisors LLC boosted its holdings in Pfizer by 0.3% during the second quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after purchasing an additional 55 shares during the last quarter. Meridian Wealth Management LLC boosted its holdings in Pfizer by 0.5% during the second quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after purchasing an additional 57 shares during the last quarter. Stone House Investment Management LLC boosted its holdings in Pfizer by 0.9% during the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 66 shares during the last quarter. Finally, Telemus Capital LLC boosted its holdings in Pfizer by 0.5% during the second quarter. Telemus Capital LLC now owns 17,888 shares of the biopharmaceutical company’s stock worth $601,000 after purchasing an additional 92 shares during the last quarter. Institutional investors and hedge funds own 69.36% of the company’s stock.

In other Pfizer news, EVP Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the transaction, the executive vice president now owns 117,432 shares of the company’s stock, valued at approximately $4,186,450.80. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the transaction, the insider now directly owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. In the last three months, insiders sold 374,621 shares of company stock valued at $12,796,098. Corporate insiders own 0.06% of the company’s stock.

Several analysts have commented on PFE shares. Deutsche Bank AG set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. BMO Capital Markets set a $37.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, October 10th. Barclays PLC set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, Jefferies Group LLC set a $38.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research report on Monday, October 16th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $38.48.

TRADEMARK VIOLATION WARNING: “Fishman Jay A Ltd. MI Sells 17,221 Shares of Pfizer, Inc. (PFE)” was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://transcriptdaily.com/2017/11/18/fishman-jay-a-ltd-mi-sells-17221-shares-of-pfizer-inc-pfe.html.

Shares of Pfizer, Inc. (PFE) opened at $35.37 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The firm has a market cap of $211,960.00, a P/E ratio of 14.15, a P/E/G ratio of 2.50 and a beta of 1.01. Pfizer, Inc. has a twelve month low of $30.51 and a twelve month high of $36.78.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. Pfizer’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.61 EPS. analysts forecast that Pfizer, Inc. will post 2.6 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.62%. Pfizer’s dividend payout ratio is presently 78.53%.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply